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ABSTRACT 
The World of medicine has gained considerable interest in the research area all over the World. Scientists constantly work on the three parameters 
‘Quality, Safety, Efficacy’ of a pharmaceutical ingredient. Refine these parameters; they are continually developing different dosage forms. These 
unique types of dosage forms help to provide improved bioavailability and efficacy of a pharmaceutical ingredient. The role of dosage form is to 
improve the availability of the medicine to treat the symptoms and disease. This article focus on the different types of dosage forms, their 
advantages and some important facts related to that dosage forms. 
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INTRODUCTION 
The world of medicine and medical science deals with the 
prevention, cure and treatment of any ailment which alters the 
functions of the human body. The word ‘Medicine’ is derived from 
the Latin word ‘Medicus’ which referred to ‘a Physician’. Medicine is 
an agent or a substance which is taken by a person by any route to 
treat the abnormal functions of the body. 
China, Babylon, Egypt and India introduced the medical science to 
the world. Indians contributed to the different type of treatments, 
diagnosis and medical ethics in the world of medical science. The 
first medical school was opened in Southern Italy in the 9th century. 
Then till the 20th
From 5000 y, Indians used Ayurvedic system of medicine and 
medical sciences. Plants, soil and clay were used to treat the 
illness. Medicine was called as ‘Aushadhi’ which can be plant 
part, soil or mixtures of some liquids which cure the disease or 
any infection. Ayurveda also tells about different dosage forms 
which are prepared by Vaidya (a physician) by applying some 
scientific knowledge. Then Vaidya mixed the ingredients derived 
from various sources by grinding, percolating or using other 
methods, prepared a dosage form which can be easily taken by 
patients. 
 century, many Universities were founded in the 
countries like Italy, France and England. This field progressed very 
rapidly after this century. 
Some dosage forms in the form of liquids like Kasaya, Arka, Sneha, 
Hima and Mantha; semi solid dosage forms like Kalka, Avaleha, 
Lepa, Malahara and Upanaha; solid dosage forms like Churna, 
Khanda Vati Lavana and Guggulu were formulated according to 
Ayurveda. In today’s World these systems are revolutionized to 
different new dosage forms from macro systems (tablets, 
capsules) to micro systems (microemulsion, microparticles) and 
then to nano systems (liposomes, nanogels) [1]. Different types of 
drug delivery systems was used as search criterion to write this 
review. Literature survey was conducted over a number of years 
1980-2020 to update and comprehensively review. The sources 
were papers from journals that are recognized world-wide. The 
keywords used as filters were-aerosols, aptamers, antisense 
therapeutics, osmotic systems, pH-activated systems, micro and 
nano drug delivery systems. 
Further more detailed form of these modern dosage forms including 
their general introduction, positive expressions is explained. 
Tablets 
Tablets are prepared by compressing the active pharmaceutical 
ingredients with or without additives. These are intended to be used 
as unit dosage forms. Tablets can be round, convex, rectangular, oval 
etc. having different sizes depending on the route of administration. 
Excipients such as diluents, binders, glidants, lubricants, 
disintegrants, sweeteners, flavours and granulating agents are used 
to formulate tablets. When the active ingredients are intended to 
protect from any type of environment in vivo/in vitro coating is done 
on the surface. The tablets are the most stable system than any other 
dosage forms. The release of active ingredients from the tablets can 
be varied by using different type of coatings and polymers [2, 3]. 
Compressed tablets 
Compressed tablets are uncoated tablets made by compressing the 
drug and excipients as a single layer or multi-layer tablets. These are 
made by direct compression technique. Since no coating is applied 
on these tablets, the release of the drug will be immediately [2, 3]. 
Sugar coated tablets 
When compressed tablets are coated with a layer of sugar is called 
as sugar coated tablets. The purpose of the coating is to mask the 
taste of bitter drug. By varying the thickness of the layer on can also 
control the release of drug from the dosage form. Sugar coated 
tablets have some features like stability of drugs and ease of 
administration when compared with film coated tablets. These 
tablets have a graceful look and act as a barrier for environmental 
changes such as oxidation and hydrolysis. The use of sugar coating is 
limited these days due to its size and weight [2-4]. 
Film coated tablets 
When compressed tablets are coated by using a thin layer of 
polymers like cellulose derivatives and control the release of drug 
from the tablet. It also has an elegant appearance like sugar coated 
tablets. It is more stable than sugar coated film and is less bulky and 
manufacturing time is less. The coating can be designed according to 
the environment in which the drug is to be released [5, 6]. 
Enteric coated tablets 
These types of tablets are coated with polymers like hydroxyl propyl 
methyl cellulose (HPMC), cellulose acetate phthalate, Eudragit L-100, 
Eudragit S-100 etc. These polymers protect the tablet from gastric 
environment and allow the release of the drug in the intestine. Drugs 
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that are prone to gastric acid are coated with enteric coated polymers. 
Enteric coated polymers also delay the release of the drug [2, 7]. 
Mouth dissolving tablets 
These are uncoated tablets that release the drug in the mouth when 
placed. These tablets disintegrate rapidly to release the drug in the 
mouth cavity before swallowing. It disintegrates into small granules 
and forms gel like structure from which the drug is released. The 
disintegration time is from seconds to some minutes [2, 8]. 
Chewable tablets 
These are intended to release the drug in the mouth or in the buccal 
cavity by chewing the tablets. These are used for the drugs that have 
large dose and size. Chewable tablets are useful for the children and 
for those who have difficulty in swallowing. To mask the taste of 
drugs, sweeteners and flavours are added. This also improves the 
patient compliance [2, 9]. 
Tablet triturates 
When active ingredients are mixed with powdered sucrose or 
lactose and then moistened, moulded into different shapes like 
cylindrical or compressed discs are known as tablet triturates. These 
are meant to be dissolved immediately. It must disintegrate rapidly 
therefore compression force should be used to lesser extent [2].  
Hypodermic tablets 
The tablets that are meant to be dissolved in distilled water to be 
injected as a solution by the parenteral route. These tablets are 
made by soluble ingredients. Sterility is the major problem with 
these types of tablets. Care should be taken to maintain its sterility 
while using these tablets [2]. 
Gelatin coated tablets 
These types of tablets are coated with gelatin to protect it from 
environmental hazards like photosensitivity. Coloured gelatin is 
used to coat the tablet. Gelatin tablets are easy to swallow and ideal 
for double-blind clinical trials and the drugs that cause irritation to 
the mucosal lining can be formulated as gelatin coated tablets. 
Gelatin coating is better than sugar or film coating [2].  
Immediate release tablets 
As the name indicates, these tablets release the drug rapidly by 
disintegrating immediately and are formulated without any rate 
controlling coating on them. Chewable tablets, effervescent tablets, 
sublingual tablets and buccal tablets are mostly used immediate 
release tablets for administration of drugs [2, 10]. 
Extended release tablets 
Controlled release, delayed release and prolonged release tablets–all 
are categorized under extended release tablets. These are designed 
to prolong the release of active ingredients in vivo at a 
predetermined rate. The release of the drug depends upon the 
physiological conditions of the body due to different type of coating 
and target to be treated. Sometimes, the drug releases in a pulsatile 
manner in order to give repeat action [11]. 
Vaginal tablets/Inserts 
Vaginal tablets or inserts are uncoated, ovoid, pear shaped tablets 
employed vaginal infections. These tablets can provide local or 
systemic effects by dissolving slowly and releasing the drug [2].  
Implant tablets 
When the tablet is inserted directly into the skin (subcutaneously) 
with the help of surgery are known as implant tablets. They slowly 
release the drug over a long period of time. They have replaced the 
traditional system of medication. These preparations are sterilized 
and mostly made by the fusion method. Hormones like testosterone 
and contraceptives are administered by using these implants. They 
are made by using rate controlling polymers and additives. 
Formulations like pallets, resorbable microparticles, polymer 
implants, in–situ gel forming implants, metal or plastic implants and 
drug eluting stents are available in the market [2]. 
Lozenges 
The term "Lozenge" derives from the French word "Losenge," which 
means a structure in the shape of a diamond with four equal sides. In 
pharmacy since the 20th century, lozenges and pastilles have been 
produced and are still under commercial production. Lozenges are 
solid preparations intended for mouth or pharynx dissolution. These 
may contain one or more drugs in a flavoured and sweetened base and 
are intended to treat local pain, mouth or pharynx infection and may 
also be used to absorb systemic drugs. We can deliver medication to 
the oral cavity or mucosal surface multi-directionally. Lozenges are 
placed in the oral cavity in a better innovative dosage form. 
Historically, lozenges have been used to relieve minor sore throat pain 
and irritation and have been widely used to provide topical 
anaesthetics and antibacterial treatment. Currently lozenges include 
the following different categories of drugs: analgesics, anaesthetics, 
antimicrobials, antiseptics, astringent antitussives, decongestants, 
demulcents, and other groups and medication combinations. These 
can be prepared by moulding (Pastilles) and compression tablets 
(Troches) depending on the type of lozenge [12-15]. 
Advantages 
1. It can be given to patients who are having trouble swallowing. 
2. Services for geriatric and pediatric use. 
3. The length of the drug in the oral cavity is prolonged to achieve a 
specific effect. 
4. Easy to plan, with minimal equipment and time required. 
5. Do not require administration of the form of water intake. 
Systemic drug absorption by the buccal cavity may be possible. 
6. Sweeteners and flavors used in the formulation that mask the 
taste of the drugs. 
7. Like parenterals, this procedure is non-invasive. 
8. While bioavailability can increase, it may decrease the dosing 
frequency. It can reduce the pain of the stomach. 
9. It can boost the start of operation. 
10. It can bypass metabolism for the first time. 
11. Increased treatment of patients. 
Classification of lozenges 
According to action site 
(a) Local impact example-Decongestants, antiseptics. 
(B) Systemic Effect example-Nicotine, vitamins. 
According to texture and composition- 
(a) Chewy or caramel-based medicinal lozenges 
(b) Compressed lozenges  
(c) Soft lozenges 
(d) Hard lozenges 
Chewy or caramel-based medicinal lozenges 
These are dosage forms in which medicinal products are 
incorporated in a caramel base that is chewed rather than dissolved 
in the mouth. The chewable lozenge, or "gummy-type" candy 
lozenge, is one of the most common lozenges for paediatric use. 
These gelatin-based pastilles were prepared by pouring the melt 
into moulds or uniform thickness onto a sheet [16, 17]. 
Compressed lozenges 
The active ingredient may be prepared by compression when it is 
heat-sensitive. The process of granulation is identical to that used 
for any tablet compressed. These tablets differ from conventional 
tablets in terms of 
• Organoleptic property, 
• 
• Profiles with gradual dissolution. 
Options that do not disintegrate 
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The lozenge is made using heavy compression equipment to give a 
tablet that is harder than usual so gradually dissolving in the mouth 
is better for the troche. Commercially, tablet compression 
preparation of lozenges is less essential.  
Soft lozenges 
Due to the ease of extemporaneous preparation and applicability to 
a wide variety of drugs, soft lozenges have become popular. The 
bases are usually a mixture of various polyethylene glycols, acacia or 
similar materials. One type of these soft lozenges is the pastille, 
described as a soft, typically transparent lozenge variety consisting 
of a gelatin, glycerogelatin or acacia medication: sucrose base. Soft 
lozenges are similar to a drug that makes the "confection" comeback. 
Confections are classified as soft masses with heavy saccharinity 
medicinal agents [13]. 
Hard candy lozenges 
Hard candy lozenges are mixtures of sugar and other carbohydrates 
in an amorphous (noncrystalline) or glassy state. They can also 
regards as solid syrups of sugar. The moisture content and weight of 
hard candy lozenge should be between, 0.5 to 1.5 % and 1.5-4.5 g 
respectively. We should be dissolved or degraded gradually and 
evenly for 5-10 min and should not disintegrate. Generally the 
temperature requirements for their preparation are high, so heat-
labile materials cannot be integrated into them. Via heating and 
congealing process these pastilles was prepared. 
Suppositories 
Suppositories are semi-solid dosage system most often placed into the 
rectum, vagina, or nasal cavity body to supply medications to the 
systemic circulation or local tissues. The drug is included into the 
suppository base and is prepared to either melt or dissolve in the body 
cavity fluid to release the drug. They are accessible in diverse weight, 
sizes and shapes. They use to produce local, systemic and mechanical 
action. These can be easily given to children, old people and 
unconscious patients who are unable to easily swallow the medication. 
These are incorporated into the body cavity to create the local effect of 
the drug in the base. These are inserted into the rectum to work 
directly and efficiently on the rectum and to facilitate bowel 
evacuation. These are unit dosage system. These are effective methods 
of administering drugs that irritate the gastrointestinal tract, cause 
vomiting and disrupt the acidic pH of the stomach juice. 
Types of suppositories 
Rectal suppositories 
For their systemic effect, these are intended to be introduced into 
the rectum. These types of suppositories are usually made from 
Theobroma oil and are available in diverse sizes to meet the needs of 
infants, adults and children. Weight of rectal suppository is usually 
1-2 g. They are either torpedo or cone shaped. 
Vaginal suppositories 
These are intended to be introduced into vaginal. Also known as 
pessaries, these suppositories are larger than rectal suppositories. 
Vaginal suppositories may be conical, rod shaped, or wedge-shaped 
and usually 4-8 of weight is available. Vaginal tablets and vaginal 
capsules that have replaced vaginal suppositories are also available 
nowadays. 
Nasal suppositories 
These are meant for nasal cavity penetration and are also known as 
nasal bougies. These are similar to the suppositories of urethra. These 
are small and cylindrical in shape and are always made with a base of 
glycero-gelatin. They are about 9-10 cm long and about 1.0 g in weight. 
Urethral suppositories 
These are meant for urethra implementation and are also referred to 
as urethral bougies. To allow insertion, these are small, long and 
cylindrical shapes at one end. Their weight ranges between 2-4 g. 
These suppositories are used very seldom. 
Ear cones 
These are intended for ear insertion and are also known as 
aurinaria. These are rarely used today. These suppositories are 
about 1 g in shape and weight, thin, long, and cylindrical. Usually 
theobroma oil is used to prepare the ear cones [18, 19]. 
Pellets 
Pelletized dosage forms date back to the 1950s, when the first 
product was introduced to the market. In 1949, research scientists 
of SmithKline and French advanced tiny drug pellets which are filled 
into capsules. Since then, these dosage forms have gained 
considerable popularity because of their distinct benefits inclusive of 
enhancement of drug dissolution. Pellets are small, free flowing, 
systematically produced, spherical or semi spherical solid units, 
geometrically defined agglomerates of about size ranging from 0.2 
mm to 2.0 mm, obtained from numerous starting materials of fine 
powders or granules of bulk drugs and excipients using different 
pelletization techniques. Pellets supposed for oral use are 
administered in the form of hard gelatin capsules or disintegrating 
tablets which rapidly liberate their contents inside the stomach and 
gets distributed all through the gastrointestinal tract without loss of 
the depot impact as the sub-unit acts as self-contained depots. 
Pellets offer greater flexibility within the design and development of 
an active element into oral dosage forms like tablets, capsules and 
suspension with significant therapeutic benefits over single units. As 
subunits various kinds of particles with described less-porous 
surface, spherical shape, and low surface area to volume ratio are 
suitable for flexible and uniform drug polymer coating [20]. 
Capsules 
The term ‘Capsule’ derived from Latin word Capsula [21]. The 
invention of the gelatin capsule is generally credited to Moths and 
Dublanc, two Frenchmen. Their patents, issued in March and 
December 1834, covered a method of producing single-piece, olive-
shaped, gelatin capsules that were closed after a drop of condensed, 
moist gelatin solution had been filled. In 1865, the two-piece 
telescopic tube, invented by London's jam Murdock, was patented in 
England [22]. In pharmacy, capsule term has been used to define a 
glass ampoule and also as a name of a protective cap over the 
stopper of a bottle of medicine. Recently, capsules have been mainly 
used to identify types of solid dosage form, consisting of a container 
which is filled with medicinal material. Capsules are divided in two 
classes,’ soft capsule’ (one piece) and ‘hard capsule’ (two piece) 
according to the presence of glycerol or another plasticizer that 
make it soft and elastic [23]. Benefits of capsules such as drugs with 
an unpleasant smell and taste can be conveniently administered; 
Less supplements are needed compared to tablets; they are 
inexpensive; once they come into contact with water, they are 
slippery and quick to swallow with water; the shells are 
physiologically inert and digested in the GIT easily and quickly; the 
shells can be opacified or coloured to provide light protection [24]. 
Ocular drug delivery system 
Ocular drug delivery systems are used for the treatment of eye 
infection/diseases by installing directly into the eye (topical, 
intraocular and periocular). Ocular preparations are sterile and free 
from particles and pyrogens. Eye drops, eye ointments, eye lotions 
etc. are the examples of ocular drug delivery systems. 
Eye drops are meant to be installed into the conjunctiva sac and can 
be hydrophilic and/or lipophilic preparations. These are sterile 
preparations which are free from any particulate matter. Drugs like 
antiseptics, anaesthetics, mydriatics and meiotic can be incorporated 
into eye drops. 
Eye Ointments are semi-solid aseptic preparations. They are 
composed of mineral oil and soft paraffin with drugs and are 
anhydrous primarily. Due to its semi-solid nature, it stays for 
prolong time in the eye and provide better bioavailability. These are 
available for single use also to avoid contamination. 
Eye Lotions are concentrated preparations used for washing of 
eyes. It can be diluted with warm water. These preparations must be 
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isotonic, sterile and free from grittiness. The pH of the solution must 
be equal to lachrymal fluid and should be non-irritant [25, 26]. 
Aerosols 
Pharmaceutical aerosols are the systems in which propellants are 
used to disperse fine drug particles into it under pressure. So 
aerosols are defined as pressurised systems containing therapeutic 
ingredients which deliver the drug in mist or gaseous form upon 
pressing the outlet valve. Sterilization can be maintained throughout 
its shelf life. By using metered dose valve, potent drugs can be 
administered with safety and accuracy. The drugs are protected 
from environmental factors like oxidation, hydrolysis and light [27]. 
Buccal drug delivery system 
Buccal drug delivery system is a system in which the drug is 
delivered through the buccal mucosa [28]. Buccal mucosa lines the 
inner area of cheeks [29, 30]. Advantages of buccal drug delivery 
system such as it avoids first-pass metabolism and enzyme 
metabolism; as compared to sub-lingual, buccal drug delivery 
system have large surface area; in case of toxicity it can be easily 
removed and easy to administer; it plays important role in that case 
in which patients are unconscious and comatose [31, 32]. 
Gastro-retentive drug delivery system 
Gastro-retentive drug delivery systems can stay in the gastric area for 
several hours, substantially increasing drug residence and prolonging 
gastric retention; enhancing bioavailability, decreasing drug waste and 
improving solubility. Gastro retention provides better availability and 
local drug delivery to stomach and intestine [33]. Categories of gastro-
retentive drug delivery system are effervescent system, non-
effervescent system, hollow microspheres/microballons and 
microporous compartment system [34]. 
These drug delivery systems offer benefits such as drug delivery in 
small intestine area with narrow absorption window. Floating 
systems are beneficial for stomach absorbed drugs e. g. antacid salt. 
Specific site intake from the upper part of the gastrointestinal time 
may lead to the development of drugs with poor bioavailability as a 
floating drug delivery system to maximize their absorption. Due to 
the long term release impact, floatability and standardized release of 
the drug through a multi-practice scheme preventing gastric 
irritation. These systems provide better therapeutic effect of short 
lived medicinal products [35]. 
Nasal drug delivery system 
Nasal drug administration has been used as a different route for the 
systemic availability of drugs constrained to intravenous 
administration. This is due to the large surface area, porous 
endothelial membrane, high total blood flow, metabolism avoidance 
and ready accessibility. Upon intranasal administration, drugs are 
quickly removed from the nasal cavity, resulting in rapid systemic 
drug absorption [36, 37]. For the following reasons, nasal delivery is 
considered a promising technique: The nose has a large surface area 
accessible for drug absorption due to the penetration of the epithelial 
surface by multiple microvilli, the subepithelial layer is highly 
vascularized, the venous blood from the nose passes directly into the 
systemic circulation and thus avoids the loss of the drug through first-
pass metabolism in the liver, allowing lower doses, quicker therapeutic 
bladder attainment, less side effects, high total blood flow per cm3
Pulmonary drug delivery system 
, 
easily accessible porous endothelial basement membrane, and drug 
delivery directly to the brain via olfactory nerves [38-40]. The 
respiratory mucosa is the perfect area for the absorption of drugs [41]. 
Drug deliveries to the respiratory tract, via inhalation, to treat the 
bronchial diseases are referred as pulmonary drug delivery systems. 
This system is very beneficial in the treatment of asthma, chronic 
obstructive broncho-pneumopathy. Therapeutic action is fast due to 
the direct administration on the site of action. These systems also 
bypass the first pass metabolism. Dose is less and ease of 
administration provides better patient compliance. Pressurized 
metered dose inhalers (pMDI) or dry powder inhalers (DPI) are the 
examples of pulmonary drug delivery systems [42]. 
Hepatic drug delivery system 
It is the type of targeted drug delivery systems. The drug is 
administered via any type of novel drug delivery systems such as 
liposomes, niosomes, microparticles etc. When the drug reaches at 
the site if action i.e. liver via blood circulation, the drug is actively 
taken by hepatic cells and cure the hepatic diseases. The delivery 
systems must be made in such a way that they only release their 
drug on target site and should be protected from harsh environment 
of other organs. The drug must accumulate within the liver cells to 
achieve the desired therapeutic concentration. Probucol liposomes, 
Mannosylated superoxide dismutase (SOD), Ursodeoxycholic acid 
(UA) modified protein-lipid nanocomplex, Super paramagnetic iron 
oxide (SPIO) nanoparticles are some drugs used to treat hepatic 
disorders [43]. 
Monoclonal antibodies 
Monoclonal antibodies are defined as the single clone molecules of a 
particular parent cell which are produced by hybridoma cells or cell 
line and is identical i.e. identical in structure, idiotype, affinity, and 
specificity for specific epitope. Monoclonal antibodies can be used 
alone or in conjugation with drugs, toxins, cytokines or isotopes. In 
the past years, the main source of the antibodies was human or 
animal blood but it had a basic issue i.e. it contains polyclonal 
antibodies meaning it can bind to several epitopes and show many 
type of immune reactions. It has advantages like one can get 
unlimited supply of single type of antibodies having specific activity 
to unlimited period of time [44, 45].  
Aptamers 
Aptamers are defined as oligonucleotides that are derived by the 
process Systematic Evolution of Ligands by Exponential Enrichment 
(SELEX). They are categorised as DNA or RNA aptamers having short 
strands of oligonucleotides and peptides aptamers having one or 
more peptide chains. Aptamers inhibits the activity of cancer cells 
and bacteria. Aptamers control the release of bio molecule 
therapeutics. But aptamers form weak bonds with the protein 
binding sites which are too weak to show its activity. They also help 
to activate the Polymerase Chain Reaction (PCR) enzymes which 
initiate the initial phases of Polymerase Chain Reaction [46, 47]. 
Antisense therapeutics 
These are defined as short length single stranded DNA or RNA 
having base sequence complementary to particular gene or its 
mRNA. Antisense oligonucleotides block the activity of ribosomal 
machinery or activate the endogenous RNAase that break the mRNA 
at duplex site by inhibiting the expression of unwanted cell protein 
by recognizing Watson–Crick complementary base and hybridize it 
to the target mRNA. The example of phosphodiester oligonucleotides 
is phosphorothioate oligodeoxynucleotides (PS-oligonucleotides) 
containing a sulphur instead of oxygen in one of the non-bridging 
phosphate. Due to this it inhibit the rapid degradation by nucleases. 
These have many properties like binding affinity to the target 
(mRNA), cellular uptake, hydrophilic and the ability to activate 
RNase H, which is required for antisense activity [48, 49]. 
Sedds, Smedds, Sndds 
These systems are formed by mixing surfactants, co-surfactants, and 
drugs and made isotropic mixtures. When this mixture comes in 
contact with water it forms microemulsion with fine droplets in the 
biological system. These are better than other lipid formulations 
because of use of surfactants. The formed droplet size of self-
emulsifying drug delivery system ranges between 100 to 300 nm 
[51]. Self-microemulsifying drug delivery system has particle size 
less than 50 nm and self-nanoemulsifying drug delivery system have 
particle size in nano range [50].  
Medium chain triglycerides are used to make self-microemulsifying drug 
delivery system because of their better solubility and self-emulsifying 
properties. Only specific type of excipients can be used to prepare self-
microemulsifying drug delivery system. Drugs that are soluble in lipid-
surfactant mixture can be incorporated in self-microemulsifying drug 
delivery system. These are transparent in nature.  
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Self-nanoemulsifying drug delivery systems are better due to patient 
compliance and are more stable. Self-nanoemulsifying drug delivery 
systems are anhydrous in nature therefore hard gelatin capsules are 
made to store the dosage form and for administration also [52].  
Vaccines 
Vaccines are the preparations made by using biological sources to 
fight against a particular disease when injected to human or animal 
by the process called vaccination. Micro-organisms that resembles 
the pathogen of disease are extracted and attenuated or killed by 
chemical processes are used to make vaccines. Vaccines can be given 
prior to the disease as prophylactic vaccines and/or can be given 
when a person catches a disease as therapeutic vaccines [53]. 
Attenuated vaccines are those made by decreasing the activity of 
virus so that it cannot cause disease itself. Examples of this type are 
typhoid, yellow fever, measles, mumps, BCG (for tuberculosis) and 
rubella [54, 55].  
Inactivated vaccines are those made by killing the bacteria or virus 
and injected into the body which stimulates the immune system to 
create immunity against that particular system. Examples are polio 
vaccine, hepatitis A vaccine, rabies vaccine and some influenza 
vaccines [56]. 
Toxoid vaccines are made by using inactivated toxic substances 
that are responsible for the disease/infection instead of bacteria or 
virus. Examples are tetanus and diphtheria [57]. 
Subunit protein vaccines are made by using only protein part of the 
bacteria or micro-organism or virus instead of using whole bacteria or 
virus. These proteins are capable of generating immune responses. 
Some subunit vaccines are subunit vaccine against Hepatitis B virus, 
the virus-like particle (VLP) vaccine against human papillomavirus 
(HPV), and the hemagglutinin and neuraminidase subunits of the 
influenza virus [58]. 
Colon targeting drug delivery system 
This drug delivery system is designed to treat the local infection in 
the lower part of the gastrointestinal tract (GIT) and minimizing the 
side effects of the drugs. This system enhances the concentration of 
the drug by protecting its absorption in upper part of the 
gastrointestinal tract and made it more available in the colon to treat 
the disease. It provides therapeutic satisfaction to the patients in 
terms of safety, efficacy, and patient compliance. The contents in the 
colon stay more than 5 d so complete drug absorption can be 
obtained but stability of the drug can be compromised [59].  
Gene drug delivery system 
The newly discovered drug delivery system is the treatment with 
genes. In this therapy, no drugs are needed to treat the disease. The 
infected genes are removed, modified or mutated and then again 
inserted in the infected cell. This leads to the fast and complete 
recovery of the disease. It is beneficial to treat the genetic problems, 
cancers and certain viral diseases. The gene delivery systems 
comprises the three substances such as a gene expression system 
that contain plasmid (that controls the function of a gene within the 
targeting cell), a gene (to encodes a specific therapeutic protein), 
and a gene delivery system (to control the delivery of the gene 
expression plasmid) to the target gene within the body [60]. 
Magnetic drug delivery system 
This drug delivery systems based on the nanoparticles with iron 
oxide as a vehicle for delivery of drugs. Single molecule magnets are 
used to transfer the toxic drug to the target site without 
incorporating the iron oxide in that site. The main problem with this 
drug delivery system is the excess concentration of iron oxide which 
leads to adverse effects. But this method is beneficial in cancer 
treatment by formulating “anticancer nanomagnet” [61]. 
Brain drug delivery system 
When the drug deliveries are designed to cross the different brain 
barriers are called as brain drug delivery systems. Highly lipophilic 
drugs can cross blood brain barriers easily and target the brain 
tumours and other infections in the brain. But due to the clearance 
of the drugs rapidly from the brain cannot maintain the therapeutic 
concentration of the drug. Barriers are the main problem for the 
delivery of the drugs to the brain. There are many micro and nano 
drug delivery systems that facilitate the delivery of hydrophilic and 
lipophilic drugs across the barriers [62]. 
Mucoadhesive drug delivery system 
Mucoadhesion is generally defined as the adhesion between two 
materials, of which at least one is a mucosal surface. Mucoadhesive 
dosage systems may well designed to enable prolonged retention at 
the site of application, providing a controlled rate of drug release for 
better therapeutic outcome. The application of dosage forms to 
mucosal surfaces may be beneficial to drug molecules that are not 
appropriate for the oral route, such as those suffering from acid 
degradation or severe first-pass metabolism. Topical and local systems 
based on Mucoadhesive have shown increased bioavailability. 
Mucoadhesive drug delivery results in fast absorption and strong 
bioavailability due to its large surface area and high blood flow. Drug 
delivery across the mucosa bypasses the first-pass hepatic metabolism 
and prevents gastrointestinal enzymes from degrading. Thus the 
mechanism of delivery of mucosal drugs could be of use in delivering a 
growing number of high-molecular-weight responsive molecules such 
as peptides and oligonucleotides. Mucoadhesive drug delivery system 
plays an important role in controlled drug delivery system [63, 64]. 
Benefits of Mucoadhesive drug delivery system such as;  
• Targeting drug delivery system;  
• High flux of drugs in the absorbing tissue 
• Good accessibility 
• Painless administration 
• Avoid first pass metabolism 
• Low enzymatic activity 
Bioactive drug delivery system 
It is defined as the system in which biomolecules like protein and 
peptides are delivered into the body. These systems are used to 
protect the bioactive molecules from the harsh environment of the 
body. Proteins and peptides (like insulin, silk molecules), 
polysaccharides, lipids, minerals etc can be delivered using systems 
like emulsions, encapsulation and others. Edible materials can be 
incorporated into this type of system. McClements et al. studied the 
delivery of bioactive compounds by emulsion based systems. They 
focussed on the materials used to formulate these systems to deliver 
the bioactive molecules in the body [65, 66]. 
Osmotic drug delivery system 
When drug release is dependent upon osmotic pressure is called 
osmotic drug delivery system. Osmotic pressure controls the release 
of the drug from the dosage form. There is a semi permeable 
membrane that controls the permeability of biological fluids. The 
substance that creates pressure to push the drug layer out of the 
system is called osmogent. The drug is delivered through the orifice 
is made by laser drilling. This type of drug delivery system is 
independent of other physiological factors. Drug release can be 
expressed as zero order release kinetics. The drug release from this 
type of dosage can be targeted, delayed as needed [67, 68].  
Transdermal drug delivery system 
Drug delivery through the skin is known as Transdermal drug 
delivery systems. The drug can be transferred through the skin via 
transdermal patches, inotophoresis, through microfibricated needles 
and electroporation. 
Transdermal patches 
A transdermal patch is a drug containing sticky patch which is 
applied on the skin and delivered the drug to the systemic 
circulation avoiding first pass metabolism. It is a painless system to 
deliver the drug to treat the problems. It improves the patient 
compliance. It can be easily removable in case of adverse effects and 
when treatment is required no longer. Controlled drug delivery can 
be achieved through this system of medication. Drug release can be 
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achieved for several days to several months. Drug release is constant 
and passively therefore therapeutic concentration can be 
maintained. The particle size of the drug must be less than 1000 
units to be incorporated into transdermal patches and the drug must 
have lipophilicity and hydrophilicity to some extent [69, 70]. 
Inotophoresis 
It is a process of applying a few miliampere of current to the 
particular part of the skin for a few milliseconds by using electrodes. 
These electrodes remain in contact with the formulation and skin 
and therefore allow the passage of the drug through skin and heal 
the problem. The example is administration of Pilocarpine and 
Lidocaine (for anaesthetic purpose). 
Micrfibricated microneedles 
This system has a drug reservoir and needle like projections 
called microneedles which extend from the drug reservoir and 
projects onto the skin. The needle like projections acts as 
microneedles and transdermal patch which help to deliver the 
drug through the skin. 
Electroporation 
Drug delivery by electroporation is assisted by using high voltage 
electric pulses. These pulses dilate the epidermis cells and make pores 
in the skin. Then the drug diffuse through these pores into the skin. 
Microspheres 
Microspheres are small spherical particles, with diameters 1 μm to 
1000 μm. They are spherical free flowing particles consisting of 
proteins or synthetic polymers which are biodegradable in nature. 
There are two types of microspheres; microcapsules and 
micromatrices, which are described as-Microcapsules are those in 
which entrapped substance is particularly surrounded by distinct 
capsule wall and micromatrices in which entrapped substance is 
dispersed during the matrix. Microspheres are every so often 
referred to as microparticles. Microspheres can be manufactured 
from various natural and synthetic materials. Microsphere plays a 
vital role to improve bioavailability of conventional drugs and 
minimizing side effects [71]. 
Advantages of microspheres 
• Particle size reduction for enhancing solubility of the poorly 
soluble drug. 
• Decrease dose and toxicity. 
• Better drug utilization will improve the bioavailability and 
reduce the incidence or intensity of adverse effects 
• Provide constant and prolonged therapeutic effect. 
• Provide constant drug concentration in blood thereby increasing 
patient compliance. 
Microcapsules 
Microencapsulation is the method of enclosing a substance 
inside a miniature known as the capsule. Microcapsule is a small 
sphere with a uniform wall around it. The material inside the 
microcapsule is referred to as the core/inner phase, whereas the 
wall is every so often called a shell/coating. The microcapsule 
size ranges from 1 µ-7 mm. All the three states i.e. solid, liquid 
and gas may also be encapsulated which may additionally have 
an effect on the size and shape of capsules. If the solid or 
crystalline material is used as the core, the resultant capsule can 
also be irregularly shaped. If the core fabric is liquid, simple 
spherical capsules containing a single droplet of encapsulate 
may additionally be formed [72]. 
Advantages of microcapsule 
 Microcapsule used for sustained or prolonged release. 
 It is also used for masking taste and odour of many drugs to 
improve patient compliance. 
 Vaporization of many volatile drugs e. g. methyl salicylate and 
peppermint oil can be prevented by microencapsulation. 
 It can reduce toxicity and GI irritation including ferrous sulphate 
and KCl. 
 It can be used for converting liquid drugs in a free flowing 
powder. 
Microsponges 
Won developed microsponge technology in 1987 andamp; filled 
original patent for the same and it is assigned to polymer system. 
Their organization developed with versions a number of 
products for pharmaceutical and cosmetic use. Microsponges 
consist of polymeric drug delivery system porous microspheres. 
They are sponge like structure consisting of a myriad of 
interconnecting voids within a non-collapsible structure with a 
large porous surface and spherical in shape. Microsponges are 
notably stable with less side effects and having ability of 
modifying drug release. The microsponges are spherical in 
nature and having particle size ranging from 5-150μm. 
Microsponges are the cross-linked, porous, polymeric 
microspheres which accumulate the flexibility to entrap a variety 
of active ingredients. They are in most cases used for topical and 
oral administration with altering release rate. The microsponges 
i.e. microsponge drug delivery system (MDDS) consist of size 5-
150 μm in diameter; with a ordinary 25 μm sphere can up to 
250000 pores and an interior structure of pore equal to 10 ft. in 
size which provides a total pore volume of 1 ml/gm. This type of 
system exhibits large reservoir within microspongic structure, 
which can be loaded with the identical weight of active 
ingredient [73]. 
Advantages of microsponges 
 Microsponges can prevent accretion of active ingredient in the 
epidermis and dermis. 
 Microsponges can reduce irritation of effective drug by 
maintaining their effectiveness. 
 Microsponges drug delivery system increases residential time 
of a drug on skin surface or in epidermis. 
 Microsponges has stable over range of pH 1 to 11, temperature 
up to 120 °C. 
 Microsponges well-matched with most vehicles and ingredients. 
 Microsponges can improve product elegance. 
 Microsponges can improve bioavailability of the drugs. 
 Microsponges have superior formulation flexibility. 
Microemulsions 
Microemulsions are clear, stable, isotropic liquid mixtures of oil, 
water and surfactant, frequently in mixture with a co-surfactant. 
The aqueous phase may also contain salt(s) and/or other 
ingredients, and the "oil" may also truly be a complex mixture of 
exclusive hydrocarbons and olefins. In contrast to regular 
emulsions, microemulsions form upon simple mixing of the 
components and do not require the high shear conditions 
generally used in the formation of ordinary emulsions. The two 
basic types of microemulsions are direct (oil dispersed in water, 
o/w) and reversed (water dispersed in oil, w/o). In ternary 
systems such as microemulsions, where two immiscible phases 
(water and ‘oil’) are present with a surfactant, the surfactant 
molecules may also form a monolayer at the interface between the 
oil and water, with the hydrophobic tails of the surfactant 
molecules dissolved in the oil phase and the hydrophilic head 
groups in the aqueous phase. As in the binary systems 
(water/surfactant or oil/surfactant), self-assembled structures of 
exclusive types can be formed, ranging, for example, from 
(inverted) spherical and cylindrical micelles to lamellar phases 
and bi-continuous microemulsions, which may also coexist with 
predominantly oil or aqueous phases [74]. 
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Advantages of micremulsions 
 Microemulsions are thermodynamically stable system and the 
stability allows self-emulsification of the system. 
 Microemulsions act as super-solvents for drug. They can 
solubilize both hydrophilic and lipophilic drugs including drugs that 
are relatively insoluble in both aqueous and hydrophobic solvents. 
 Use of microemulsion as delivery systems can improve the 
efficacy of a drug, allowing the total dose to be reduced and thus 
minimizing side effects. 
 The dispersed phase, lipophilic or hydrophilic (oil in-water, 
O/W, or water-in-oil, W/O microemulsions) can act as a potential 
reservoir of lipophilic or hydrophilic drugs, respectively. Drug 
release with pseudo-zero-order kinetics can be obtained, depending 
on the volume of the dispersed phase, the partition of the drug and 
the transport rate of the drug. 
Microneedles 
Microneedles (MNs) have been studied by means of various 
researchers for delivering drug through the transdermal route and 
for overcoming the limitations of the conventional approaches. 
Microneedle device consists of needles of micron size, which are 
arranged on a small patch. Considering the issues of the hypodermic 
needle and the transdermal patch, microneedle drug delivery system 
was developed and is thought to be the hybrid of both. The most 
important problem related with transdermal technological know-
how is that many of the drugs are not capable to cross the pores and 
skin at the required rate integral for the therapeutic action. 
Researchers have developed a refined technological know-how the 
use of microneedles, which permit hydrophilic high molecular 
weight compounds to enter into the stratum corneum. 
Administration of drugs using the microneedle device allows the 
drug molecules to cross the stratum corneum layer, hence allowing 
more drug molecules to enter the skin. The characteristic facts of 
this technology are the faster onset of action, better patient 
compliance, self-administration, improved permeability and efficacy. 
Large molecules can be administered. First-pass metabolism is 
avoided. Decreased microbial penetration as compared with a 
hypodermic needle, the microneedle punctures only the epidermis 
and enhanced drug efficacy may result in dose reduction [75]. 
Microparticles 
Microparticles are a type of drug delivery systems where the particle size 
ranges from one micron (one thousandth of mm) to a few mm. This 
microencapsulation technology allows protection of drug from the 
environment, stabilization of sensitive drug substances, elimination of 
incompatibility, or masking of unpleasant taste. Hence, they play an 
important role as drug delivery systems aiming at improved 
bioavailability of conventional drugs and minimizing side effects [76]. 
Microballoons 
Microballoons are gastro retentive drug-delivery systems with non-
effervescent approach. Microballoons (Hollow microsphere) are in 
strict sense, empty particles of spherical shape without core. These 
microspheres are generally free flowing powders comprising of 
proteins or synthetic polymers, ideally having a size less than 200 
micrometer. Microballoons are considered as one of the most 
beneficial buoyant systems with the special advantages of multiple 
unit systems as well as better floating properties, because of central 
hollow area interior the microsphere. Novel methods concerned in 
their preparation include easy solvent evaporation method, 
emulsion-solvent diffusion method, single emulsion technique, 
double emulsion technique, phase separation coacervation 
technique, polymerization technique, spray drying and spray 
congealing technique and hot melt encapsulation method. The 
gradual release of the drug at desired rate and higher floating 
properties in most cases depends on the kind of polymer, plasticizer 
and the solvents employed for the preparation. Polymers such as 
polylactic acid, Eudragit R S and hydroxy propyl methyl cellulose 
acetate are used in the formulation of hollow microspheres, and the 
release of drug can be modulated by using optimizing polymer 
concentration and the polymer-plasticizer ratio.  
Advantages such as reduced dosing frequency and thereby improve 
the patient compliance; better drug utilization will improve the 
bioavailability and reduce the incidence or intensity of adverse 
effects, and despite the first-pass pass effect because fluctuation in 
plasma drug concentration is avoided, a desirable plasma drug 
concentration is maintained by continuous drug release. Hollow 
microspheres are used to decrease material density and Gastric 
retention time is increased because of buoyancy. Site-specific drug 
delivery to stomach can be achieved [77]. 
Microchips 
Microchip drug delivery system is the most wonderful system of 
delivering the drug for a great span of time without the intervention of 
the patient to whom it is fixed. It consists of varied number of sockets 
containing drug (generally ranging from 50-300) 
which release the drug at the fixed intervals each at a time. The 
microchip delivery system consists of a substrate containing more 
than one reservoir capable of holding chemical substances in the solid, 
liquid, or gel form. Each reservoir is capped (i.e. with a conductive 
membrane) and wired with the final circuitry controlled by a 
microprocessor. This central processor should be able to actively 
control electrically the exact time of release and the amounts of drugs 
dispersed through controlling the dissolution of the gold membrane. 
The system should be reasonable to manufacture by standard micro 
fabrication techniques and still be cost-effective [78]. 
Syrups 
Syrups are concentrated solutions of sugar such as sucrose in water 
or other aqueous liquid. Due to sweetness, can masks the taste of 
salty and bitter tablets and therefore serve as fine tasting 
automobile. Used as care for pediatric use due to their excessive 
viscosity and the “smoothness” and mouth feel quality. Enhance the 
flavor Due to the wide kind of flavors of syrups which include 
orange, lemon, peppermint, those are broadly acceptable. 
• Simple syrups: when water is used alone for making syrup. 
• Medicated syrup: Syrup with some medicinal substance. 
• Flavored syrup: Syrup with some aromatic or pleasantly 
flavored substances and is intended to be used as a vehicle or flavor 
for prescription. 
Suspensions 
A Pharmaceutical suspension is a coarse dispersion in which interior 
segment is dispersed uniformly at some point of the external phase. 
The internal phase consisting of insoluble strong particles having a 
specific range of size which is maintained uniformly throughout the 
suspending vehicle with aid of single or combination of suspending 
agent. The external phase (suspending medium) is generally aqueous 
in some instance, may also be an organic or oily liquid for non oral use. 
Deflocculated suspension: In this system, solids are present as 
individual particles. They also exhibit aggregation, but 
comparatively at a slower rate than the flocculated particles. These 
systems have a shorter shelf life, but have greater bioavailability 
when compared to flocculated systems. 
Flocculated suspension: In this system particles aggregate 
themselves by chemical bridging. These flocs are light, fluffy 
conglomerates which are held together by weak van Waals forces 
of attraction. Aggregation is achieved by adding flocculating 
adding flocculating agents. For instance, by the addition of more 
anions on to positively charged deflocculated particles flocculation 
can be achieved. This system possesses better physical stability 
characteristics, because the dissolution of flocs is a prerequisite for 
drug absorption [79].  
Emulsions 
Emulsions are two-phase system in which the dispersed phase is 
also liquid. Emulsion are defined as thermodynamically unstable 
systems consisting of at least two immiscible liquid phases, one of 
which is dispersed as globules the other liquid phase. Large number 
of emulsion is present in nature. Examples are milk, rubber latex, 
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crude oil etc. Emulsion should be used when both phases, dispersed 
and continuous, are liquids. In an emulsion, one liquid (the 
dispersed phase) is dispersed in the other (the continuous phase). 
Examples of emulsions include vinaigrettes, homogenized milk, and 
some cutting fluids for metal working. 
Water-in-Oil Emulsion: An emulsion is referred to as water-in-oil, if 
the dispersed phase (Internal phase) is water and the continuous 
phase (dispersed medium) is oil. Examples are butter, salad 
dressings. w/o emulsion are generally meant for external use, 
though a few examples of internal use are available. 
Oil-in-Water Emulsion: An emulsion is referred to as oil-in-water, if 
the dispersed phase (internal phase) is oil and the continuous phase 
(dispersed medium) is an aqueous base. These types of emulsion are 
meant for both internal and external use [80, 81]. 
Multiple emulsions 
Multiple Emulsions are complex vehicle systems in which o/w and 
w/o emulsions exist in a single system. Lipophilic and hydrophilic 
surfactants are exploited for stabilizing multiple emulsions
Liniments 
. Water-
in-oil emulsions can be stabilized by lipophilic (oil-soluble, low HLB) 
surfactants, while o/w systems are stabilized by hydrophilic (water-
soluble, high HLB) surfactants. Multiple emulsions are “emulsions of 
emulsions,” in wherein the drops of the dispersed phase themselves 
contain smaller dispersed droplets of a miscible liquid. Every 
dispersed globule in the double emulsion makes a vesicular 
structure with single or multiple watery compartments divided from 
the aqueous phase via an oil phase layer. In multiple emulsion 
system, solute has to transverse from inner miscible phase to outer 
miscible phase by the middle immiscible organic phase; it is also 
known as liquid membrane system. There are two important types 
of multiple emulsions: w/o/w and o/w/o double emulsions. 
Multiple emulsions are mainly used in cosmetics, pharmaceuticals, 
and food. Due to their fine texture, they exhibit a smooth touch upon 
application. In cosmetics, they can protect an active ingredient from 
degradation and release it at a controlled rate. They can act as an 
internal depot and entrap compounds from the outer diluted 
continuous phase into the inner space [82]. 
Liniment is a liquid that you rub into the skin in order to reduce pain or 
relieve stiffness. Liniments can be rubbed into the skin to relieve aches 
from arthritis and stiffness in muscles. A liniment is usually in the form of 
a thin liquid applied to the skin. Liniment is a medicated topical 
preparation for application to the skin. Sometimes called balm or heat 
rubs, liniments are of a similar or greater viscositythan lotions and are 
rubbed in to create friction, unlike lotions, ointments or creams, 
but patches, sticks and sprays are also available [83]. 
Ointments 
Ointments are viscous, semisolid preparations containing both 
dissolved and suspended purposeful ingredients. The ointment base 
needs to be heated to above its melting temperature prior to the 
addition of the other ingredients. Low-shear or blending speed is 
generally used when the ointment bases or completed formulation 
in cold/thick. Mixing speed and shear can be elevated while the 
ointment base is liquid, to uniformly disperse the practical 
ingredients. Mixers used for ointments generally rent dual-motion 
counter-rotating blades with side scrapers, to maintain the fabric in 
constant motion and provide efficient warmness transfer from the 
partitions of the mixing vessel. External powder educators may be 
used to incorporate stable ingredients. All ointments consist of a 
base which chiefly acts as a carrier for the medicaments. The nature 
of the base also controls its performance. Hence selection of 
ointment base is very important aspect of their formulation. For 
scientific understanding of per-cutaneous absorption of ointment 
bases it is essential to get familiar with skin structure in relation to 
drug absorption. They provide means of site specific application of 
drug on affected area, which avoids unnecessary non target 
exposure of drug thereby avoiding side effects. They avoid first pass 
metabolism of drug. This is the convenient method for unconscious 
patients having difficulty in oral administration. Comparatively they 
are chemically more stable and easy to handle than liquid dosage 
forms. They are suitable dosage forms for bitter taste drugs [84]. 
Gels 
Gels are described as semi rigid systems wherein the movement of 
the dispersing medium is restricted through an interlacing three 
dimensional networks of particles or solvated macromolecules of 
the dispersed phase. 
The word “gel” is derived from “gelatin” and both “gel” and “jelly” 
can be drawn again to the Latin gelu for “frost” and gel are, meaning 
“freeze” or “congeal”. This origin shows the important idea of a 
liquid setting to a solid-like material that does not flow, however is 
elastic and retains some liquid characteristics. Use of the term “gel” 
as a class originated at some point of the overdue 1800s as chemists 
tried to classify semisolid substances according to their 
phenomenological characteristics instead of their molecular 
compositions. At that time, analytical methods wished to determine 
chemical structures have been lacking. In pharmaceutical 
applications, water and hydro-alcoholic solution is most common 
many polymer gels showcase reversibility between the gel state and 
sol, which are the fluid segment containing the dispersed or 
dissolved macromolecule.  
However, the formation of some polymer gels is irreversible because 
their chains are covalently bonded. The three dimensional network 
formed in two-phase gels and jellies is formed by numerous inorganic 
colloidal clay. The formation of those inorganic gels is reversible.  
Ideally, the gelling agent must be inert, safe and cannot react with 
other formulation constituents. The gelling agent should produce a 
sensible solid-like nature at the time of storage which is easily 
broken when exposed to shear forces produced by squeezing the 
tube, trembling the bottle or at the time of topical application. It 
should have suitable anti-microbial agent. The topical gel must not 
be sticky. The ophthalmic gel must be sterile. The apparent viscosity 
or gel strength increases with an increase in the effective crosslink 
density of the gel. However, a rise in temperature may increase or 
decrease the apparent viscosity, depending on the molecular 
interactions between the polymer and solvent. They exhibit the 
mechanical characteristics of the solid state. Each component is 
continuous throughout the system. There is high degree of attraction 
amongst the dispersed phase and water medium so the gels remain 
equally uniform upon standing and doesn’t freely settle [85]. 
Hydrogels 
Hydrogels that is polymer networks drastically swollen with water. 
Hydrophilic gels which are normally referred to as hydrogels are 
networks of polymer chains which might be sometimes observed as 
colloidal gels wherein water is the dispersion medium. Hydrogels 
are polymeric material that exhibits the capability to swell and 
retain a significant fraction of water within its structure, however 
will no longer dissolve in water. Hydrogels have received 
considerable attention within the past 50 y, due to their first-rate 
promise in a wide variety of applications. 
The ability of hydrogels to absorb water arises from hydrophilic 
functional groups attached to the polymeric backbone, while their 
resistance to dissolution arises from cross-links between network 
chains. Many materials, each naturally taking place and synthetic, fits 
the definition of hydrogels. It has the highest absorption capacity 
(maximum equilibrium swelling) in saline. One can get the desired rate 
of absorption (preferred particle size and porosity) depending on the 
application requirement. Hydrogels has highest biodegradability 
without formation of toxic species following the degradation [86]. 
Dendrimers 
The term dendrimer comes from the Greek word 'Dendron,' which 
means a tree. The synonym for Dendrimer is 'Arborols,' which also 
means a tree and 'Cascade molecule'. Dendrimers are repetitively 
branched molecules consisting of a monomer attached centre where 
a diameter in the range of 2 to 10 nm leads to a mono-disperse, tree-
like, star-like molecules. A dendron typically contains a single group 
called the focal point (branching points) that can be chemically 
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handled. The first dendrimers Synthesis did by divergent synthesis 
approaches by Fritz Vögtle in 1978, R. G. Denkewalter at Allied 
Corporation in 1981, Donald Tomalia at Dow Chemical in 1983 and 
in 1985, and by George Newkome in 1985. In 1990 a convergent 
synthetic approach was introduced by Jean Fréchet. 
Polyamidoamines (PAMAM) were the first synthesized dendrimers. 
Simultaneously, the Newkome group documented synthesis of 
related macromolecules that they called “arborols” [87, 88]. 
Advantages 
1. In the range of 1-100 nm, dendrimers particle size in nanometer 
crosses the cell membrane easily. 
2. Reduced clearance due to small scale through the Reticulo-
Endothelial System (RES).  
3. Dendrimer is the ideal carrier for a core-protected dysfunctional 
drug.  
4. It is monodispersed.  
5. Dendrimer increases poorly soluble drug solubility.  
6. There are several functional groups on the outer surface of 
dendrimers that can be used to attach vector devices to target 
specific body locations [89, 90]. 
Types of dendrimer 
1. PAMAM Dendrimer  
2. PAMAMOS Dendrimer 
3. P PI Dendrimer  
4. Tecto Dendrimer  
5. Chiral Dendrimers  
6. Hybrid Dendrimers  
7. Liquid Crystalline Polymers  
8. Amphiphilic Dendrimers  
9. Micellar Dendrimers  
10. Multiple Antigen Peptide Dendrimers  
11. Frechet-Type Dendrimers  
12. Multilingual Dendrimers [91-94]  
Nanoparticles 
There has been a growing interest in the use of nanoparticles for 
drug delivery applications in recent decades. Nanoparticles are 
particles of colloidal size with diameters ranging from 1-1000 nm 
and may contain, absorb or disperse drugs. A wide range of 
nanoparticles have been produced, consisting of a variety of 
materials, resulting in delivery systems that differ in their 
physicochemical properties and therefore in their applications [95, 
96]. To date, a number of drug delivery mechanisms, including but 
not limited to liposomes, micelles, nanospheres, niosomes, 
nanocapsules, solid lipid nanoparticles, microemulsions and carbon 
nanotubes, have been studied. Such systems ' success is due in part 
to the several advantages they provide to distribute their product 
payload. The nano-sized versatility of these delivery systems allows 
them to be directly delivered into the systemic circulation without 
the possibility of blocking blood vessels. The size of the nanoparticle 
has been shown to be a significant factor in determining the particles 
in vivo fate. Researchers have shown that opsonization and 
subsequent macrophage recognition and phagocytosis are strongly 
correlated with particle size. Nanoparticles have the potential of 
addressing and remedying some of the most significant limitations 
of traditional chemotherapy, namely, its lack of specificity and 
narrow window of therapeutic efficacy. Nanoparticles are colloidal 
carriers with dimensions on the nano scale (10-9
Advantages 
 m) [97, 98]. 
1. Nanoparticles drug carriers have higher stability. 
2. Nanoparticles have higher carrier efficiency. 
3. Facility of integration of both hydrophilic and hydrophobic 
substances. 
4. Nanoparticles are biodegradable, non-toxic and can be stored for 
longer periods. 
5. Nanoparticles reduce dosage frequency and have higher dosage 
frequencies. 
6. Nanoparticles can also be used for controlled drug delivery. 
Liposomes 
Liposomes are composed of amphiphilic molecules consisting of polar as 
well as non-polar components which form colloidal particles. This self-
assembly produces a spherical structure that includes the polar 
components of the molecule and the non-polar components that touch 
the non-polar world. The most popular liposome distinction is the 
number of lipid bilayers in the colloidal form, with unilamellar liposomes 
containing one lipid bilayer and multiple liposomes with multiple lipid 
bilayers. Because of their amphiphilic nature, liposomes can encapsulate 
polar as well as non-polar compounds for delivery (Lasic, 1998). For 
many purposes, liposomes are desirable among drug delivery 
applications, including their similarity to both structure and composition 
of cell membranes. In addition, liposomes can easily be produced with 
amphiphilic molecules that are non-toxic, non-immunogenic, normal and 
biodegradable (Haley and Frenkel, 2008; Lasic, 1998). The size of a 
liposome ranges from 20 nm up to several micrometers [99-101]. 
Advantages 
1. Providing preferential passive targeting for tumor tissues. 
2. Increased efficacy and therapeutic index.  
3. Increased stability by encapsulation. 
4. Reduction in encapsulating agent toxicity. 
5. Increased pharmacokinetic effects.  
6. Used as carriers for controlled and sustained drug delivery. 
7. Can be converted into different sizes. 
Classification of liposomes 
1. Multilamellar vesicle (MLVs)-This consists of several bilayers 
with a size ranging from 100 nm-20 m.  
2. Small unilamellar vesicles (SUVs)-This consists of a single 
lipid bilayer with a dimeter varying from 20-100 nm.  
3. Large unilamellar vesicles (LUVs)-Consists of a single bilayer 
with a diameter varying from 0.1-1 m. 
4. Multivesicular vesicles (MVVs)-It consists of vesicles ranging 
from 100 nm to 20 m in size. 
Transfersomes 
The name is derived from the Latin word ‘transfere’ meaning ‘to 
carry across’ and the Greek word ‘soma’ for a ‘body’. Transferosomes 
are a particular type of liposomes that consist of edge activator and 
phosphatidylcholine [102]. They are flexible, malleable vesicles 
designed to improve active agent delivery. Transferosome is a 
complex aggregate that is highly adjustable, responsive to stress. 
Transferosomes have a joint infrastructure of hydrophobic and 
hydrophilic molecules and can therefore provide accommodation 
drug molecules with extensive range of solubility [103]. Without 
observable loss, transferosomes can deform and move through 
narrow constriction from 6 to 11 times lower than their own 
diameter [104, 105]. This high deformability gives intact vesicles a 
greater penetration. Tranferosomes have a high efficiency of 
trapping, which is almost 90% for lipophilic drugs. Transferosomes 
protect the encapsulated medication from metabolic degradation. 
These have been commonly used as a carrier for various proteins, 
anti-cancer drugs, anti-fungal drugs, analgesics, anaesthetics, 
corticosteroids, sex hormone, insulin, albumin, etc. with the brilliant 
delivery properties of transferosomes [106, 107]. 
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Nanospheres 
A polymeric nanosphere can be characterized as a matrix-type, solid 
colloidal particle in which drugs are dissolved, trapped, 
encapsulated, chemically bound or adsorbed to the polymer matrix 
of the constituent [108-110]. Usually, these particles are larger than 
micelles with diameters between 100 and 200 nm and can also show 
substantially more polydispersion [111]. The main aims of 
developing the Nanospheres as a target delivery system to monitor 
the particle size and the release of pharmacologically active agents 
to achieve the site specific action of the drug at the therapeutically 
optimal rate and dosage regimen [112, 113]. 
Advantages 
1. Due to their extremely small volume, nanospheres can easily 
pass through the smallest capillary vessels [114,115]. 
2. We should prevent rapid phagocyte removal in order to prolong 
the length of the bloodstream. 
3. It is easy for nanospheres to penetrate cells and tissue gaps to 
enter target organs, eg. Liver, spleen, liver, lymph and spinal cord. 
4. It shows the property of the controlled release. 
5. Site-specific targeting by adding the ligands to the sphere’s surface. 
6. Each path, including oral, nasal, parenteral, etc, can be easily 
administered. 
7. A significant advantage of nanospheres is also the elimination of 
toxicity [116]. 
Nanoemulsion 
Nanoparticle formulation is effectively based on nanometric-scaled 
emulsion, so-called nano-emulsions, the study of nanoparticle 
formulation has to include knowledge of nanoemulsion formation 
governing phenomena. Nano-emulsions are nanometric-sized 
emulsions, typically exhibiting diameters of up to 500 nm. Nano-
emulsions are also often referred to as miniemulsions, fine-
dispersed emulsions, submicron emulsions and so on, but are all 
characterized by high suspension stability due to their very small 
size, which is mainly the result of substantial steric stabilization 
between droplets, which explains why the Ostwald ripening process 
is the only adapted droplet destabilization process. Consequently, 
nano-emulsion systems can be viewed as a blueprint for the 
generation of nanoparticles, even though these two phases can often 
be merged into one. Thus, the countless variants of the formulation 
of nanoparticles are based mainly on three different groups of 
methods for nanoemulsion generation, i.e. high-energy methods, 
low-energy spontaneous emulsification process. The inverse 
temperature (PIT) is low-energy step process [117-119]. 
Advantages 
1. Ease of scale-up and limited batch-to-batch variability. 
2. Narrow scale nanoparticulate drug distribution. 
3. Flexibility in the management of product quality. 
4. Applied selectively to thermolabile compounds. 
5. Taste masking. 
6. Non toxic and non irritant. 
7. Enhances the bioavailability of the drug. 
Solid lipid nanoparticles 
In 1991, Solid lipid nanoparticles were introduced and they represent 
different carrier systems to traditional carriers such as liposomes, 
micro and nanoparticles, emulsion [120]. As a novel colloidal drug 
carrier for intravenous applications, nanoparticles made from solid 
lipids are attracting great attention because they have been proposed 
as an alternative particulate carrier system [121]. Solid Lipid 
Nanoparticles are colloidal submicron carriers ranging from 50-1000 
nm, consisting of physiological lipid, distributed in water or in an 
aqueous surfactant solution [122]. SLN offers unique properties such 
as small size, large surface area, high drug loading and step interaction 
at the interface, and is desirable for their potential to improve 
pharmaceutical performance. The use of solid lipids as the drug 
delivery matrix content is well known from lipid pellets for oral drug 
delivery (e. g. Mucosolvanw retardation capsules) [123].  
Benefits of solid lipid nanoparticles 
1. Control and target drug release from the system. 
2. Brilliant biocompatibility 
3. Increase steadiness of pharmaceuticals 
4. Superior drug content 
5. Manufacturing is much easier than biopolymeric nanoparticles.  
6. Special solvent not required [124]. 
Nanostructure lipid carrier 
Nanostructure Lipid Carriers are the second generation lipid nano 
carriers consisting of solid lipid matrix filled with liquid lipids. NLCs 
are able to firmly immobilize drugs and prevent particles from 
coalescing as opposed to emulsions by virtue of the solid matrix. 
Mobility of the drug molecules incorporated in the solid phase is also 
significantly reduced. Additionally, droplets of liquid oil in the solid 
matrix increase the drug load capacity relative to SLNs. NLCs also have 
benefits over polymeric nanoparticles, including low toxicity, 
biodegradability, drug safety, controlled release and avoidance during 
development of organic solvents. NLCs have been studied intensively 
as hydrophilic and hydrophobic drug delivery carriers [125]. 
Niosomes 
Niosomes are vesicles that consist mainly of non-ionic hydrated 
surfactants, in addition to cholesterol (CHOL) or its derivatives in 
many cases. The specific structures of niosomes allow both 
hydrophilic and lipophilic substances to be encapsulated. This can be 
done by encapsulating hydrophilic substances in the vesicular 
aqueous core or adsorbing them on the bilayer surfaces while the 
lipophilic substances are encapsulated by partitioning them into the 
bilayer's lipophilic domain. Thin lipid film or lipid cake is hydrated 
and liquid crystalline bilayers stacks are liposome-forming, swelling, 
and flowing. Agitation divides and self-associates the hydrated lipid 
sheets to form vesicles, preventing water contact with the bilayer's 
hydrocarbon center at the edges. In recent years, niosomes have 
been one of the prominent vesicles in all vesicular systems, taking on 
a great deal of interest as potential drug delivery systems for various 
routes of administration. This is because niosomes do not have the 
many drawbacks that others have and are a very effective drug 
delivery system with various applications; niosomes are capable of 
clogging specific types of drugs, genes, proteins and vaccines [126]. 
Advantages 
1. Niosomes are osmotically active, chemically stable and have a 
long storage time compared to liposomes. 
2. Their surface formation and alteration is very simple due to 
their hydrophilic head functional groups. 
3. They are highly compatible with biological systems and have 
low toxicity due to their non-ionic nature. 
4. They are also biodegradable and non-immunogenic.  
5. They can trap lipophilic drugs in aqueous compartments into 
bilayer vesicular membranes and hydrophilic drugs. 
6. We can enhance the therapeutic efficacy of drug molecules by 
shielding the drug from the biological environment, leading to 
enhanced availability and controlled drug delivery by reducing drug 
effects on target cells in selected carriers and delaying circulation 
clearance in sustained drug delivery. 
7. Unlike phospholipids, surfactant handling does not require 
special precautions and conditions. 
8. Improves product bioavailability in the oral and skin. 
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9. Niosomes can improve the absorption of certain drugs across 
cell membranes, locate them in targeted tissues and avoid the 
reticuloendothelial system [127-129]. 
Gold nanoparticles 
Nanocarriers have developed a novel platform for the delivery of 
therapeutic agents to specific targets [130]. Many delivery vehicles 
have been developed over the last decade based on various 
nanomaterials, such as polymers [131], dendrimers [132], liposomes 
[133], nanotubes [134] and nanorods [135]. Gold nanoparticles 
(GNPs) have recently emerged as an attractive candidate for delivering 
unique payloads within their goals. The payloads may be small drug 
molecules or large biomolecules, such as proteins, DNA, or vide post 
RNA [136, 137]. Such therapeutic agents ' performance release is a 
requirement for effective therapy. The release may be caused by 
internal stimuli (e. g. glutathione (GSH) [138] or pH [139]) or external 
stimuli (e. g., light [140]). For example, in the monolayer, a gold 
nanoparticle with a core diameter of 2 nm could in principle be 
combined with average100 molecules to available ligands. Zubarev et 
al. recently succeeded in combining average70 molecules of paclitaxel, 
a chemotherapy drug, with a GNP with a core diameter of 2 nm. 
Quantum dots (QDs) 
Quantum dots are tiny semiconductors particles a few nanometers 
in size, having optical and electronic properties that differ from large 
particles due to quantum mechanics. They are central topics in 
nanotechnology. When UV light illuminates the quantum dots, a 
quantum dot electron can be excited to a higher energy state. This 
process corresponds to the transition of an electron from the 
valance band to the conductance band in the case of a 
semiconducting quantum point. The excited electron can drop back 
into the valence band and release its energy by light emission. The 
light’s color depends on the difference in energy between the 
conductivity and the valance band. Nanoscale semiconductor 
materials tightly contain either electrons or electron holes in the 
language of materials science. Quantum dots are sometimes referred 
to as artificial atoms, emphasizing their singularity, having binding, 
discrete electronic states, such as atoms or molecules that occur 
naturally. It has been shown that the electronic wave functions in 
quantum dots are similar to those in the real atoms. By coupling two 
or more such quantum dots, an artificial molecule can be made, 
hybridizing even at room temperature. Quantum dots have 
intermediate properties between large semiconductors and discrete 
atoms or molecules. Their optoelectronic properties change as a 
function of size and shape. Larger QDs with diameter of 5-6 nm emit 
longer wavelengths with colors like orange or red. Smaller QDs (2-3 
nm) emit shorter wavelengths, resulting in blue and green colors. 
However, the specific colors vary depending on the exact 
composition of the QD [141].  
Example: For in vivo use of semiconductor quantum dots are imaging 
of tumor vasculature, imaging of tumor-specific membrane antigens, 
as well as imaging of sentinel lymph nodes. Multicolor fluorescence 
imaging of cancer cells can be accomplished by systemic injection of 
quatum-dot based multifunctional nanoprobes [142]. 
Nanoshells 
Nanoshells are nanoparticles that are optically tunable and consist 
of a dielectric core and a shell of thin metal. These particles can 
primarily be designed to scatter or absorb light based on the 
dimensions of the core and shell. A larger core results in a greater 
contribution of scattering to total extinction, whereas a smaller core 
typically includes absorbing properties. The location within the 
spectrum of peak extinction depends on the core radius ratio to shell 
thickness. A thinner shell causes the peak extinction to shift to 
longer wavelengths, whereas a thicker shell produces a peak 
blueshift [143]. Due to their ability to disperse or absorb light, 
nanoshells have great potential for both imaging and therapeutic 
applications, specifically optical imaging and photothermal tumor 
ablation. Other applications include tissue welding [144] and probes 
for antigen detection in whole blood [145]. 
Nanotues 
Graphite is a well-known example of this, but now carbon can form 
closed and open cages with a honeycomb arrangement beside graphite 
[146]. Graphene is known in the list of carbon nanomaterials as 2D 
single graphite layer. Graphene is stronger than diamond material 
because it contains sp2 hybridisation that is stronger than diamond sp3
Parenteral drug delivery system 
 
hybridisation [147]. Carbon nanotubes are among the most exciting 
areas of research in recent decades [148]. Carbon nanotubes consist of 
carbon, and it is a material shaped by a tube. It has too small a 
diameter and is measured by nanoscale.  
The term parenteral formed outside from the Greek word “para” and 
intestine “enterone”. Parenterals are sterile solutions or medication 
suspension in aqueous or oily vehicles. Parenteral medications are 
delivered directly into lungs, muscles or under the skin, more 
advanced tissues such as the spinal cord. Term used for any fluid/drug 
that does not use the alimentary canal to enter the body tissue. 
Pyrogens, substances causing fever, primarily lipopolysaccharides 
formed by microorganism metabolism; they may be insoluble, soluble 
or colloidal. Parenteral administration routes usually start more 
quickly than other administration routes [149, 150]. 
Advantages 
a) Useful for patients who are unable to take drugs orally. 
b) Fast start of action. 
c) Useful in emergency situations. 
d) Continuous drug delivery. 
e) Prevent metabolic first-passing 
f) Can inject drugs directly into the tissue 
g) Can be used to administer fluids 
h) Electrolytes or nutrients in hospitals 
i) Outpatient infusion centers and home health facilities 
j) Better bioavailability 
 
 
Fig. 1: Different types of routes for parenteral drug delivery 
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Classification of parenterals 
1. Small volume parenterals (SVPs)  
2. Large volume Parenteral (LVPs) 
1. Small volume parenterals-A small intravenous injection volume is 
added to an injection packed in containers defined as 100 ml or less. 
 
 
Fig. 2: Different types of small volume parenterals 
 
Large volume parenterals 
These are parenterals intended to supply air, calories, electrolytes. 
These are sterile, non pyrogenic, free from particulate matter 
injections having volume 101-1000 ml. 
 
 
Fig. 3: Different types of large volume parenterals 
 
Ethosomes 
Touitou et al. discovered and created ethosomes in 1997 [151]. They 
can be described as non-invasive new delivery carriers that allow 
drugs to be transferred to and through deep skin layers and/or 
systemic circulation. Ethosomes are vesicular carriers consisting of 
hydroalcoholic or hydro/alcoholic/glycolic phospholipids with a 
relatively high concentration or combination of alcohols [152]. 
These are soft, malleable vesicles that are tailored to improve the 
delivery of active agents. For many years, the vesicles are well 
known for their importance in cellular communication and particle 
transport. Vesicles would also allow the release rate of the drug to 
be regulated over an extended period of time, keep the drug 
protected from immune response or other removal mechanisms and 
thus be able to release the correct amount of drug and maintain the 
concentration steady for a long time. The size range of ethosomes 
varies from tens of nanometers (nm) to microns (μ) [153, 154]. 
Benefits of Ethosomes 
1. Contains a mixture of non-toxic raw material. 
2. Targeted drug delivery system. 
3. Controlled drug delivery system. 
4. The ethosomal technology is immediately available for marketing. 
5. Good compliance with patients: the ethosomal drug is delivered 
in a semi-solid form (gel or cream) resulting in high patient 
compliance. 
6. Ethosomal drug delivery system can be widely used in the fields 
of pharmaceutical, veterinary, cosmetic [155, 156].  
Pulsatile drug delivery systems 
Pulsatile drug delivery system is that system which releases the drug 
in ‘pulse’ form which means a ‘lag time’ before releasing the drug and 
then complete release of the drug from the system. The release of the 
drug form these systems are mostly depend upon the environmental 
changes in vivo. Time controlled, stimuli induced, externally regulated 
systems are made to achieve this type of drug release profile. pH-
dependent systems and micro flora dependent systems are the 
examples of pulsatile drug delivery systems. These types of systems 
are useful in various diseases like bronchial asthma, myocardial 
infarction, angina pectoris, arthritis and hypertension, because in 
these diseases, the level of hormones and other factors increases and 
decreases with time. So, pulsatile systems are very useful to control 
the attacks at that particular time [157, 158].  
Bucky balls 
In September 1985 Bucky balls were first discovered 
experimentally. Bucky balls are a fullerene form with Formula C60
Lymphatic carrier drug delivery system 
. It 
has a cage that resembles a soccer ball, consisting of twenty 
hexagons and twelve pentagons, with a carbon atom with one Π 
bond and two σ bonds at each corner of the structure to create a 
universal vertex [159]. Fullerenes are inert and hollow, and can be 
modified indefinitely. They are not absorbed when administered 
orally in water-soluble form; while on the i. v. Injection, they spread 
rapidly to different body tissues. They excrete via the kidney 
unchanged. It was found that the acute toxicity of water-soluble 
fullerenes was fairly low. All of these interesting properties offer the 
possibility of using fullerenes in biology and medicinal chemistry 
and promise a bright future as medicinal agents for fullerenes. Bucky 
balls are the third form of carbon, and have become the most 
popular science and technology molecules. Nowadays, bucky balls 
are a key topic in nanotechnology and industrial research because of 
their very practical. Fullerenes are already used in today's industry, 
mostly in cosmetics, where they play a significant role as 
antioxidants [160, 161].  
The delivery of drugs and bioactive compounds via the lymphatic 
system is complex and depends on the nature of the system 
physiologically. The lymphatic path plays an important role in 
transporting extracellular fluid to preserve homeostasis and moving 
immune cells to injury sites, preventing first-pass metabolism and 
thus serving as a bypass route for compounds with lower 
bioavailability, i.e. those suffering from more hepatic metabolism. 
The lymph route also provides an option for the delivery of 
therapeutic molecules, such as cancer treatment drugs and the 
human immunodeficiency virus, which can travel through the lymph 
system [162]. The targeting of the lymph system through 
subcutaneous, intestinal and pulmonary routes was assessed and 
subsequently used to enhance the lymph penetration and retention 
of drug molecules, minimize drug-related systemic toxicity and 
increase the bioavailability of poorly soluble and unstable drugs 
[163]. 
Intrauterine device (IUD) 
An intrauterine device (IUD) is a small T-shaped birth 
control device, which is placed in the woman's uterus to prevent 
pregnancy. IUDs are one form of long-acting reversible birth control 
(LARC). IUDs are safe and effective in adolescents as well as those 
who’ve not formerly had children. Once an IUD is removed, even 
after long-term use, fertility returns to normal rapidly. There are 
two types IUD 
Non hormonal (Copper containing IUD) 
Most copper IUDs have a T-shaped frame it wound be around with 
pure electrolytic copper wire and/or has copper collars (sleeves). 
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The arms of the frame hold the IUD in place near the top of the 
uterus., copper acts as a spermicide within the uterus by increasing 
levels of copper ions, prostaglandins, and white blood cells within 
the uterine and tubal fluids. The increased copper ions in the 
cervical mucus inhibit the sperm's motility and viability, preventing 
sperm from traveling through the cervical mucus, or destroying it as 
it passes through. Copper can also alter the endometrial lining, but 
studies show that while this alteration can prevent implantation of a 
fertilized (blastocytes), it cannot disrupt one that has already been 
implanted. It is the most effective form of emergency contraception 
available. It works by preventing fertilization or implantation but 
does not affect already implanted embryos. It contains no hormones, 
so it can be used while breastfeeding and fertility returns quickly 
after removal. Copper IUDs also last longer and are available in a 
wider range of sizes and shapes compared to hormonal IUDs. The 
possibility of heavier menstrual periods and more painful cramps. 
Hormonal IUDs work by liberating a small amount of drug 
(levonorgestrel). Each kind varies in size, amount of levonorgestrel 
released, and duration. The primary mechanism of action is making 
the inside of the uterus uninhabitable for sperm. They can also thin 
the endometrial lining and potentially impair implantation but this is 
not their usual function. Because they fine the endometrial lining, 
they can also reduce or even prevent menstrual bleeding [164, 165].  
CONCLUSION 
Different drug delivery systems have been used to provide health 
benefits to the society since decades. As the world of medicine 
grows, the newer system of delivering the drugs has been 
discovered to solve the problems like safety and efficacy of the 
newer invented active pharmaceutical ingredients. Every coin has 
two sides just like every delivery system, but to avoid those 
limitations newer inventions come into this world. The newer 
systems then avoid the limitations of prior systems. In the end, we 
can say that the allopathic system of medicines is growing towards 
new heights. 
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